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Introduction In the last years, the Cu(I)-catalyzed Huisgen [3+2]
cycloaddition between terminal alkynes and azides emerged as a
powerful tool in F-18 radiolabelling of biomolecules such as peptides,
because of its regioselectivity, mild aqueous organic conditions, re-
duced reaction times, and high yields.(1).A weak point of the method
is the lack of suitable commercially available, stable precursors.(2) In
this paper we report the synthesis and F-18 radiolabelling of a new,
versatile, easy to handle, and stable azido precursor useful for click-
chemistry.
Materials and methods: Reagents and solvents were purchased
from Sigma-Aldrich. [18F]Fluoride was produced with an IBA Cyc-
lone 18/9 cyclotron. Radioactive synthesis were carried out on a
fully automated radiosynthesis module (GE TracerLab FX-FN Pro),
and analyzed by analytical RP-HPLC with UV and radiochemical
detectors. Non-radioactive compounds were fully characterized by
NMR, ESI-MS and IR.
Results: A series of bifunctional precursors, bearing the azido moiety
and different leaving groups (e.g. tosylate, mesylate, iodo), coupled
to a short polyetyleneglycol chain (to improve their stability and
hydrophilicity) were designed and successfully prepared following a
ten-step synthetic pathway. A protection-deprotection strategy of
functional groups achieved the precursors and the fluorinated refer-
ence with good yield and purity. Precursors were radiolabelled with
F-18 and then coupled to propargylglycine as alkyne counterpart.
[18F]Fluoride was purified following standard procedure, and nucleo-
philic displacement of the iodo leaving group took place at 100° C,
in 20 min. The resulting labelled azide was successfully purified using
a Sep-Pak tC18 cartridge (51% radiochemical yield not decay cor-
rected, 93% radiochemical purity). The purified azide was then conju-
gated to propargylglycine, showing 52% conversion within 30 min at
room temperature. Purification and formulation have still to be
optimized.
Discussion/conclusion: A new optimized precursor useful for F-18
radiolabelling and click-chemistry was prepared. It demonstrated to
be effective in radiolabelling non-protected alkynyl-modified aminoa-
cids, by a fully automated synthetic procedure. Good results, in terms
of radiochemical yield and purity, were obtained from the iodo-
derivative precursor. Purification and formulation of the final cyclo-
addition product are in progress.
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Introduction: Radiopharmaceuticals are released for administration
by a quality control procedure against pre-set specifications. One of
these release specifications is the chemical purity of the drug prod-
uct, determined with High Pressure Liquid Chromatography (HPLC)
and UV detection. In the European Pharmacopeia (EP) hardly any
specifications are given for the chemical purity of a radiopharmaceu-
tical. When unknown impurities are present in the chromatogram,
the decision if the radiopharmaceutical can be released, is very fre-
quently based on unclear parameters like ‘no unidentified UV signals
present’. There is a need for an objective specification in order to
have a save and reliable release.
Aim: The purpose of the presented work is to define a generally
applicable method to define tolerances for unidentified impurities in
radiopharmaceuticals.
Materials and methods: A retrospective analysis was performed on
HPLC analysis results of [11C]Flumazenil, [11C]PIB, [11C]Erlotinib,
[11C]DPA713, [18F]PK209 and [18F]FES. Quantification of the carrier
signal in the UV chromatogram was determined by use of calibration
curves, utilizing Chromeleon® 6.8. Unidentified impurities were semi-
quantified utilizing the surface area in the UV chromatogram relative
to the quantified carrier signal. Based on the EP. monography of
[11C]Flumazenil and [18F]FET, the specification for unidentified UV
impurities was determined to be 0.22 pmol/injection volume for a
single unidentified impurity and 0.88 pmol/injection volume for the
total of unidentified impurities. This specification was tested for over
500 batches of the radiopharmaceuticals and compared to the less
specific parameter ‘no unidentified UV signals present’.
Results: In a pilot assessment we encountered in 5-10% cases
unidentified UV impurities leading to rejection of the batch,
based on the specification ‘no unidentified UV signals present’.
Of these rejected batches 25% was also rejected with the new
defined specification. Reason for this reduced number of rejec-
tions is that with the new specification the presence of unidenti-
fied impurities is evaluated objectively. The analysis of the full
database is currently on-going.
Discussion/conclusion: With this method the amount of unidentified
impurities can be estimated in an optimal and objective way, utiliz-
ing EP limits of [11C]Flumazenil and [18F]FET, without operator
variability.
OP13
Development of [18F]Fluoro-C-glycosides to radiolabel peptides
Collet C.1,2, Petry N.1,3, Chrétien F.1,3, Karcher G.1,2,4, Pellegrini-Moïse N.1,3,
Lamandé-Langle S.1,3
1Université de Lorraine, F-54500 Vandoeuvre les Nancy – France;
2NancycloTEP, Plateforme d’imagerie expérimentale, 54500 Vandoeuvre
les Nancy – France; 3CNRS, UMR 7565 SRSMC, F-54506 Vandoeuvre les
Nancy – France; 4CHU de Nancy-Brabois, F-54511 Vandoeuvre les
Nancy – France
Correspondence: Collet C. – Université de Lorraine, F-54500
Vandoeuvre les Nancy – France
EJNMMI Radiopharmacy and Chemistry 2016, 1(Suppl 1):OP13
Introduction: The 18F-labeling of peptides for PET applications has
been used for many years.1 However, the sensitivity of these pep-
tides does not allow their direct radiolabelling under harsh condi-
tions, except few recent examples. A solution is to use a prosthetic
group, an easily radiolabeled small molecule, subsequently coupled
in mild condition to the peptide. In continuation of our previous
work,2 we therefore propose to develop and use new C-glycoside-
based prosthetic groups. The use of sugar derivatives as prosthetic
group would improve bioavailability and pharmacokinetic properties
of peptides.
Materials and methods: These C-glycoside derivatives should have a
good leaving group thus allowing easy substitution by fluorine-18,
i.e. triflate. A copper catalyzed azide alkyne cycloaddition (CuAAC)
was then used for coupling these carbohydrates with a peptide.
Some model peptides containing a cysteine residue as RGDC and
c(RGDfC) are used. The high nucleophilicity of the thiol function can
thus be exploited to prepare S-propargylated derivatives. The fully
automated radiosynthesis of these [18F]fluoro-glycopeptides was per-
formed on an AllInOne® (Trasis) synthesizer.
Results: Triflated precursors of these C-glucosides prosthetic groups
and the non-radioactive references were synthesized in alpha and
beta configuration. Fluoride-18 radiolabeling was optimized and the
automated radiosynthesis of [18F]fluoro-glycopeptides with some
model peptides (RGDC, c(RGDfC)) was presented.
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 4 of 37
